Monte Rosa Therapeutics Inc. is a pharmaceutical company based in the USA that specializes in developing molecular glue degraders (MGDs) using artificial intelligence and proprietary experimental tools. With a diverse library of over 50,000 MGD molecules, their product candidate MRT-2359 targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus on ESG principles drives them in advancing their pipeline of MGDs to offer novel therapeutic modalities for various diseases. Their risk rating score of 29.3 signifies medium risk assessment.